Semaglutide Research for Appetite Control
An evidence-based overview of research examining Semaglutide in the context of appetite control. This page synthesizes findings from peer-reviewed literature.
Research Summary
Semaglutide's weight loss efficacy is primarily mediated through central appetite suppression. The drug activates GLP-1 receptors in the hypothalamus, specifically affecting POMC/CART (satiety) and NPY/AgRP (hunger) neuronal pathways. Clinical studies demonstrate 20-35% reduction in caloric intake. Patients report reduced hunger, increased fullness, and decreased food cravings. The drug also delays gastric emptying, prolonging post-meal satiety. These appetite effects are sustained during treatment but reverse after discontinuation, which is why weight regain occurs when the drug is stopped. This suggests semaglutide is managing appetite rather than permanently resetting hunger signals.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Appetite Control
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Semaglutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.